GM-CSF administration augments the survival of ity-resistant A/J mice, but not ity-susceptible C57BL/6 mice, to a lethal challenge with Salmonella typhimurium.
Ity resistant A/J mice were challenged with a lethal dose (2 x 10(3) organisms) of Salmonella typhimurium. Infected mice treated with 1 microgram of GM-CSF twice daily showed increased median survival time and had a higher survival fraction than untreated controls. GM-CSF was most effective when given for a brief period (1 to 2 days) after infection. Pretreatment of the mice or delayed treatment with GM-CSF had no effect on the survival of the mice. Studies on the effect of GM-CSF on the bacterial load showed that mice treated with GM-CSF had fewer S. typhimurium in the spleen and peritoneal cavity on day 4 but not on day 2 after infection. GM-CSF treatment of ity-susceptible C57BL/6 mice infected with 10 organisms had no therapeutic effect.
Immunex Corporation, Seattle, WA 98101.
P J
PJ
Morrissey
K
K
Charrier
D000818:Animals; D003115:Colony-Stimulating Factors / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006133:Growth Substances / Q000627:therapeutic use*; D051379:Mice; D008805:Mice, Inbred A / Q000276:immunology*; D008810:Mice, Inbred C57BL / Q000276:immunology*; D010529:Peritoneal Cavity / Q000382:microbiology; D012481:Salmonella Infections, Animal / Q000235:genetics / Q000276:immunology* / Q000382:microbiology; D013154:Spleen / Q000382:microbiology; D016019:Survival Analysis
D003115:Colony-Stimulating Factors; D006133:Growth Substances; D016178:Granulocyte-Macrophage Colony-Stimulating Factor